1. Home
  2. DLPN vs NCEL Comparison

DLPN vs NCEL Comparison

Compare DLPN & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dolphin Entertainment Inc.

DLPN

Dolphin Entertainment Inc.

HOLD

Current Price

$1.10

Market Cap

19.1M

ML Signal

HOLD

NCEL

NewcelX Ltd. Ordinary Shares

N/A

Current Price

$3.15

Market Cap

17.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DLPN
NCEL
Founded
1996
2008
Country
United States
Switzerland
Employees
N/A
4
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.1M
17.2M
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
DLPN
NCEL
Price
$1.10
$3.15
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
16.3K
27.9K
Earning Date
05-15-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
77.87
N/A
EPS
N/A
N/A
Revenue
$56,699,389.00
N/A
Revenue This Year
$14.73
N/A
Revenue Next Year
$7.41
N/A
P/E Ratio
N/A
N/A
Revenue Growth
9.70
N/A
52 Week Low
$0.99
$1.83
52 Week High
$1.88
$5.12

Technical Indicators

Market Signals
Indicator
DLPN
NCEL
Relative Strength Index (RSI) 32.93 52.32
Support Level $1.06 $2.95
Resistance Level $1.67 $3.62
Average True Range (ATR) 0.09 0.23
MACD 0.00 -0.00
Stochastic Oscillator 28.79 75.00

Price Performance

Historical Comparison
DLPN
NCEL

About DLPN Dolphin Entertainment Inc.

Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.

About NCEL NewcelX Ltd. Ordinary Shares

NewcelX Ltd is a clinical-stage biopharmaceutical company focused on developing transformative therapies. Built on a validated human pluripotent stem cell (hPSC) platform, the Company's main program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. It is advancing a comprehensive therapeutic approach for Type 1 Diabetes, integrating cell therapy, immune protection, and translational science, including a phase IIa clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS) in the field of regenerative medicine, as well as the development of treatments for Central Nervous System (CNS) disorders, including Narcolepsy, utilizing its Doxa platform. Its products are Holistic, IsletRx, AstroRx, and the DOXA platform.

Share on Social Networks: